Table 2.
Patient Clinical and Quality-of-Life Measurements (Total N = 120)
| Measure mean (SD) |
Total Sample (n = 120) |
GOLD Stage 1 (n = 23) |
GOLD Stage 2 (n = 53) |
GOLD Stage 3 (n = 27) |
GOLD Stage 4 (n = 17) |
ANOVA | ANOVA | KWT | |
|---|---|---|---|---|---|---|---|---|---|
| F-stat | RE | p-value | p-value | ||||||
| FEV1 (%) | 58.4 (24.8) | 92.9 (13.7) | 65.5 (9.1) | 37.4 (5.7) | 23.0 (4.8) | 254.2 | <0.001 | <0.001 | |
| 6MWT (m) | 312.5 (108.0) | 356.7 (124.3) | 321.0 (95.8) | 315.0 (98.8) | 222.5 (89.6) | 6.01 | <0.001 | <0.001 | |
| Borg Dyspnea | 2.48 (1.64) | 1.19 (1.11) | 2.33 (1.65) | 3.48 (1.67) | 3.12 (0.49) | 11.55 | <0.001 | <0.001 | |
| SGRQ Total | 41.3 (19.7) | 28.8 (15.0) | 37.2 (18.6) | 52.2 (19.6) | 54.1 (13.5) | 11.15 | Ref | <0.001 | <0.001 |
| SGRQ Symptom | 50.0 (24.1) | 42.4 (21.4) | 46.8 (23.9) | 60.1 (26.1) | 54.4 (20.2) | 2.98 | 0.27 | 0.03 | 0.02 |
| SGRQ Activity | 57.3 (27.6) | 38.0 (23.8) | 53.5 (28.1) | 65.7 (23.0) | 82.5 (10.0) | 12.36 | 1.11 | <0.001 | <0.001 |
| SGRQ Impact | 29.9 (18.9) | 19.4 (14.9) | 25.8 (16.3) | 41.9 (20.0) | 37.8 (17.5) | 9.34 | 0.84 | <0.001 | <0.001 |
| SF-36 PCS | 34.4 (9.6) | 39.5 (10.1) | 34.4 (10.7) | 32.4 (7.8) | 30.9 (4.2) | 3.49 | 0.31 | 0.02 | 0.002 |
| SF-36 MCS | 49.6 (10.9) | 52.60 (9.4) | 50.5 (10.4) | 47.9 (12.5) | 45.5 (10.7) | 1.75 | 0.16 | 0.16 | 0.114 |
| EQ-5D US Index | 0.73 (0.19) | 0.80 (0.13) | 0.70 (0.21) | 0.72 (0.19) | 0.72 (0.16) | 1.35 | 0.11 | 0.26 | 0.079 |
| EQ-5D UK Index | 0.63 (0.27) | 0.73 (0.19) | 0.59 (0.32) | 0.63 (0.25) | 0.63 (0.24) | 1.38 | 0.12 | 0.25 | 0.069 |
| EQ-5D VAS | 65.3 (18.9) | 74.3 (16.3) | 66.2 (20.0) | 60.1 (18.4) | 58.7 (15.8) | 3.31 | 0.30 | 0.02 | 0.004 |
GOLD: global burden of obstructive lung disease; Ref: Reference; RE: Relative efficiency ratio; SGRQ: St. George's Respiratory Questionnaire; ref: reference; ANOVA: analysis of variance; KWT: Kruskal-Wallis test